Cytogenetic effects in children treated with methylphenidate

Randa A. El-Zein, Sherif Z. Abdel-Rahman, Matthew J. Hay, Mirtha S. Lopez, Melissa L. Bondy, Debra L. Morris, Marvin S. Legator

Research output: Contribution to journalArticlepeer-review

82 Scopus citations


In recent years there has been a surge in methylphenidate (Ritalin) use for treatment of attention deficit/hyperactivity disorder (ADHD) in children. However, there is a paucity of information on whether this drug poses any potential health risks, such as mutagenicity or carcinogenicity, for humans. To address this issue, we investigated whether this central nervous system stimulant produces cytogenetic abnormalities in pediatric patients at therapeutic levels. In a population composed of twelve children treated with therapeutic doses of methylphenidate, we analyzed three cytogenetic endpoints in peripheral blood lymphocytes obtained before and three months after initiation of treatment with this drug. In all participants, treatment induced a significant 3, 4.3 and 2.4-fold increase in chromosome aberrations, sister chromatid exchanges and micronuclei frequencies, respectively (P=0.000 in all cases). These findings warrant further investigations of the possible health effects of methylphenidate in humans, especially in view of the well-documented relationship between elevated frequencies of chromosome aberrations and increased cancer risk.

Original languageEnglish (US)
Pages (from-to)284-291
Number of pages8
JournalCancer Letters
Issue number2
StatePublished - Dec 18 2005
Externally publishedYes


  • ADHD
  • Children
  • Chromosomal aberrations
  • Genotoxicity
  • Methylphenidate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cytogenetic effects in children treated with methylphenidate'. Together they form a unique fingerprint.

Cite this